A PROSPECTIVE STUDY OF THE NATURAL COURSE OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN RENAL ALLOGRAFT RECIPIENTS1
暂无分享,去创建一个
H. Rollag | A. Hartmann | P. Fauchald | T. Leivestad | M. Degré | K. Osnes | A. Foss | E. Holter | K. Nordal | S. Sagedal
[1] H. Rollag,et al. Immunologic parameters as predictive factors of cytomegalovirus disease in renal allograft recipients. , 1999, The Journal of infectious diseases.
[2] C. Sabin,et al. Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: Relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG) , 1999, Journal of medical virology.
[3] J. Squifflet,et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. , 1999, The New England journal of medicine.
[4] D. Snydman,et al. Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. , 1998, The Journal of infectious diseases.
[5] J. Chavez,et al. Cytomegalovirus pneumonia in renal transplant patients. , 1998, Transplantation proceedings.
[6] Chul-woo Yang,et al. Clinical Course of Cytomegalovirus (CMV) Viremia with and without Ganciclovir Treatment in CMV-Seropositive Kidney Transplant Recipients , 1998, American Journal of Nephrology.
[7] M. Schnitzler,et al. Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant recipients. , 1998, The Journal of infectious diseases.
[8] E. Thorsby,et al. A strong impact of matching for a limited number of HLA-DR antigens on graft survival and rejection episodes: a single-center study of first cadaveric kidneys to nonsensitized recipients. , 1998, Transplantation.
[9] A. Hartmann,et al. Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation. , 1998, Transplantation.
[10] M. Schnitzler,et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. , 1997, Transplantation.
[11] R. Venuto,et al. Monitoring and diagnosis of cytomegalovirus infection in renal transplantation. , 1997, Journal of the American Society of Nephrology : JASN.
[12] K. Yuen,et al. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay. , 1997, Clinical transplantation.
[13] M. Kunz,et al. Importance of simultaneous active cytomegalovirus and Epstein-Barr virus infection in renal transplantation. , 1996, Clinical and diagnostic virology.
[14] D. Snydman,et al. Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Cytomegalovirus Antibody-Positive Renal Transplant Recipients , 1995, Annals of Internal Medicine.
[15] H. Rollag,et al. Influence of cytomegalovirus antibody status on graft survival in renal transplantation. , 1994, Transplantation proceedings.
[16] R. Hené,et al. Factors influencing the occurrence of active cytomegalovirus (CMV) infections after organ transplantation , 1993, Clinical and experimental immunology.
[17] D. Pillay,et al. THE PROGNOSTIC SIGNIFICANCE OF POSITIVE CMV CULTURES DURING SURVEILLANCE OF RENAL TRANSPLANT RECIPIENTS , 1993, Transplantation.
[18] R. Écochard,et al. Cytomegalovirus infection--an etiological factor for rejection? A prospective study in 242 renal transplant patients. , 1993, Transplantation.
[19] D. Dunn,et al. Treatment of recurrent cytomegalovirus disease in patients receiving solid organ transplants. , 1993, Archives of surgery.
[20] W. V. van Son,et al. Preemptive therapy with gancyclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroid-resistant rejection after renal transplantation. , 1993, Transplantation proceedings.
[21] R. Schooley,et al. SYMPTOMATIC CYTOMEGALOVIRUS DISEASE IN THE CYTOMEGALOVIRUS ANTIBODY SEROPOSITIVE RENAL TRANSPLANT RECIPIENT TREATED WITH OKT31,2 , 1992, Transplantation.
[22] R. Rubin. Impact of cytomegalovirus infection on organ transplant recipients. , 1990, Reviews of infectious diseases.
[23] M. van der Giessen,et al. Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation--a report of 130 consecutive patients. , 1989, Transplantation.
[24] P. Griffiths,et al. SYMPTOMATIC CYTOMEGALOVIRUS INFECTION IN SEROPOSITIVE KIDNEY RECIPIENTS: REINFECTION WITH DONOR VIRUS RATHER THAN REACTIVATION OF RECIPIENT VIRUS , 1988, The Lancet.
[25] A. Levey,et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. , 1987, The New England journal of medicine.
[26] H. Rollag,et al. The role of the tumor necrosis factor system and interleukin-10 during cytomegalovirus infection in renal transplant recipients. , 2000, The Journal of infectious diseases.
[27] T. Howard,et al. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. , 1997, Journal of the American Society of Nephrology : JASN.
[28] C. Portal,et al. Cytomegalovirus preemptive therapy with ganciclovir in renal transplant patients treated with OKT3. , 1996, Nephron.
[29] E. Olding-Stenkvist,et al. Diagnostic markers and risk factors of cytomegalovirus infection and disease in renal allograft recipients. , 1995, Scandinavian journal of infectious diseases.